Botanix Pharma are dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Their mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles.
Botanix are harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Argonaut were engaged to raise capital for Botanix in 2017 and 2018. The Placement was strongly supported by Australian based investors, which resulted in the Placement being significantly oversubscribed. Funds from the Placement will enable Botanix to continue to execute its key clinical development programs and accelerate its broader commercialisation strategy.
Argonaut | Perth
Level 30, Allendale Square, 77 St Georges Terrace Perth, WA, 6000 Australia
ABN 72 108 330 650